finanzen.net

Advaxis das sieht gut..

Seite 1 von 1
neuester Beitrag: 06.06.15 12:36
eröffnet am: 13.01.14 10:43 von: Bäcker33 Anzahl Beiträge: 25
neuester Beitrag: 06.06.15 12:36 von: fbo|2288627. Leser gesamt: 5358
davon Heute: 2
bewertet mit 2 Sternen

13.01.14 10:43
2

3622 Postings, 5621 Tage Bäcker33Advaxis das sieht gut..

13.01.14 10:50

69 Postings, 2022 Tage Sizzla81Chart sie sehr gut aus...

Gibt es weitere News?  

13.01.14 11:04

3622 Postings, 5621 Tage Bäcker33Advaxis to Present

Advaxis to Present at Biotech Showcase? 2014 in San Francisco

By Business Wire,  January 08, 2014, 07:45:00 AM EDTVote upPRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that the Company will present at the Biotech Showcase? 2014 Conference being held at the Parc 55 Wyndham San Francisco Union Square Hotel in San Francisco, CA.Read more: http://www.nasdaq.com/press-release/...o-20140108-00168#ixzz2qGsM7AmT  

13.01.14 11:16

3622 Postings, 5621 Tage Bäcker33seit oktober

kommen die umsätze auch in gang  

13.01.14 18:22

3622 Postings, 5621 Tage Bäcker33so

ADXS Basic Chart | Advaxis, Inc. Stock - Yahoo! Finance
Access the chart for Advaxis, Inc. (ADXS) in line, bar or candlestick type. Customize the date range from 1 day, 5-day, 1-month, 3-month, 5-month or more. Perform chart performance comparison with other stocks or market indices.
4, 36 ausbruch... mal schaun ob sie es hält  

14.01.14 07:44

3622 Postings, 5621 Tage Bäcker33stark

.gegen den markt gestern  

14.01.14 14:58

3622 Postings, 5621 Tage Bäcker33200

15.01.14 14:34

3622 Postings, 5621 Tage Bäcker33schaffen

wir die 5 heute ?  

15.01.14 18:32

3622 Postings, 5621 Tage Bäcker33so

ADXS Technical Analysis | Advaxis, Inc. Stock - Yahoo! Finance
Get the chart for Advaxis, Inc. (ADXS) and see various technical analysis indicators including MACD, MFI, ROC, RSI, Slow Stoch, Fast Stoch and overlays such as bollinger bands, parabolic SAR, moving average and EMA.
200 line bei 5, 16 geknackt  

16.01.14 14:25

3622 Postings, 5621 Tage Bäcker33bye

rating  

21.01.14 13:42

3622 Postings, 5621 Tage Bäcker33news

Advaxis Announces First Patient Dosed in Phase 1/2 Head and Neck Cancer Study
By Business Wire,  January 21, 2014, 07:30:00 AM ED


Read more: http://www.nasdaq.com/press-release/...y-20140121-00243#ixzz2r2ICUw4g  

23.01.14 15:26

3622 Postings, 5621 Tage Bäcker33seek

Advaxis, Inc. (ADXS): Advaxis And Inovio Race For First Cervical Cancer Immunotherapy - Seeking Alpha
Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks
 

20.03.14 10:31

737 Postings, 3529 Tage millemaxkönnte heut kleines Stück up gehen...

...nach dem gestern nachbörslich gemeldeten Pet-Deal...
die Vorbörse wird ja schonmal den Weg zeigen:)  

20.03.14 10:48

737 Postings, 3529 Tage millemaxNe Menge Geld kommt da rein für so eine...

...noch kleine Company...ausserdem zeigt es das Potential für weitere
License Verträge:

KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer.  Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis.  Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma.

Under the agreement, Aratana made a one-time upfront payment to Advaxis of $1 million and an additional $1.5 million equity investment in Advaxis common stock and warrants.  Aratana agreed to pay up to an additional $6 million in clinical and regulatory milestones for each of the four products, assuming approvals in both cats and dogs in both United States and the European Union.  In addition, Aratana agreed to pay up to $28.5 million in commercial milestones.  Upon regulatory approval and commercialization of the immunotherapies, Aratana agreed to pay Advaxis a tiered royalty ranging from mid-single digit to 10% on net sales.
 

20.03.14 10:51

737 Postings, 3529 Tage millemaxim best case 37 mio...

...+ Royalties on net sales!
bei einer Marketcap. von 68 mio.$ von Advaxis ist das schon eine Hausnummer!  

20.03.14 15:21

737 Postings, 3529 Tage millemaxhab alles verkauft bei 5 $...

...Aktie, welche bei so einer Meldung ins Minus rutscht stinkt zum Himmel..
ob geshortet, manipuliert oder kein Interesse ist mir wurscht...  

31.03.14 14:15

519 Postings, 2072 Tage biotech1x1millemax

Gut gemacht. Der jetzige Preis lädt aber zum Wiedereinstieg ein. biotech  

03.03.15 17:51

3622 Postings, 5621 Tage Bäcker33das is

doch mal ne gute jahres perf. oder?  

06.06.15 12:36

6 Postings, 1509 Tage fbo|228862719kann man so sagen :)

   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Microsoft Corp.870747
Daimler AG710000
Scout24 AGA12DM8
Wirecard AG747206
Amazon906866
Apple Inc.865985
TeslaA1CX3T
Allianz840400
BMW AG519000
NEL ASAA0B733
E.ON SEENAG99
BayerBAY001
Infineon AG623100
SAP SE716460